{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:45:47Z","timestamp":1789343147554,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077035"],"award-info":[{"award-number":["22077035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373146"],"award-info":[{"award-number":["82373146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073310"],"award-info":[{"award-number":["82073310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117240","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:19:09Z","timestamp":1736209149000},"page":"117240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma"],"prefix":"10.1016","volume":"285","author":[{"given":"Jing-Zan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1666-8844","authenticated-orcid":false,"given":"Wen-Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117240_bib1","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117240_bib2","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2021012854","article-title":"Requirements for operational cure in multiple myeloma","volume":"138","author":"Mohty","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117240_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/ph16030415","article-title":"Past, present, and a glance into the future of multiple myeloma treatment","volume":"16","author":"Challagundla","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.117240_bib4","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.3390\/cancers14194919","article-title":"Second primary malignancy risk in multiple myeloma from 1975 to 2018","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117240_bib5","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117240_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.117240_bib7","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.3390\/cancers13194978","article-title":"Management of adverse events and supportive therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Pozzi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117240_bib8","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/cancers15072160","article-title":"Management of relapsed-refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice","volume":"15","author":"Dima","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117240_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110687","article-title":"The selective activator protein-1 inhibitor T-5224 regulates the IRF4\/MYC axis and exerts cooperative antimyeloma activity with bortezomib","volume":"384","author":"Tang","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.117240_bib10","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117240_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12185-024-03812-1","article-title":"Comprehensive analysis of microRNAs modulated by histone deacetylase inhibitors identifes microRNA-7-5p with anti-myeloma effect","volume":"120","author":"Yamada","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.117240_bib12","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3390\/biomedicines9121857","article-title":"Thalidomide exerts anti-inflammatory effects in cutaneous lupus by inhibiting the IRF4\/NF-\u04a1B and AMPK1\/mTOR pathways","volume":"9","author":"Domingo","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.117240_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2025.117240_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor","volume":"12","author":"North","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117240_bib15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117240_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114053","article-title":"A review on the treatment of multiple myeloma with small molecular agents in the past five years","volume":"229","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117240_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2025.117240_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115875","article-title":"Advances in research on potential inhibitors of multiple myeloma","volume":"262","author":"Tang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117240_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ng1097-226","article-title":"Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma","volume":"17","author":"Iida","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.117240_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma-biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2025.117240_bib21","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.3390\/cancers14174314","article-title":"IRF4 as an oncogenic master transcription factor","volume":"14","author":"Wong","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117240_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejmech.2025.117240_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41420-020-00400-0","article-title":"Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis","volume":"7","author":"Ishiguro","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.117240_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104594","article-title":"Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis","volume":"380","author":"Tang","year":"2022","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ejmech.2025.117240_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acsmedchemlett.8b00345","article-title":"Synthesis of cyanoenone-modified diterpenoid analogs as novel Bmi-1-mediated antitumor agents","volume":"9","author":"Yang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117240_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114323","article-title":"Synthesis of heterocyclic ring\u2212fused analogs of HMG499 as novel degraders of HMG-CoA reductase that lower cholesterol","volume":"236","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117240_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/nass\/nrl129","article-title":"Studies of DNA recognition mechanism of transcription factor IRF-4","volume":"50","author":"Furuita","year":"2006","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.ejmech.2025.117240_bib28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/nar\/gkaa1287","article-title":"Structural determinants of the IRF4\/DNA homodimeric complex","volume":"49","author":"Sundararaj","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.117240_bib29","first-page":"140","article-title":"Revlimid (lenalidomide) now FDA approved as first-line therapy for patients with multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.ejmech.2025.117240_bib30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1186\/s12885-021-09039-1","article-title":"IRF4-activated TEX41 promotes the malignant behaviors of melanoma cells by targeting miR-103a-3p\/C1QB axis","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2025.117240_bib31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12288-023-01628-3","article-title":"Clinical relevance of interferon regulatory family-4 (IRF4) Expression in newly diagnosed patients with multiple myeloma","volume":"39","author":"Abdelmonem","year":"2023","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.ejmech.2025.117240_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112077","article-title":"Roles of IRF4 in various immune cells in systemic lupus erythematosus","volume":"133","author":"Xiao","year":"2024","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2025.117240_bib33","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.immuni.2013.04.009","article-title":"Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4","volume":"38","author":"Ochiai","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2025.117240_bib34","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.4049\/jimmunol.2100440","article-title":"An IRF4-MYC-mTORC1 integrated pathway controls cell growth and the proliferative capacity of activated B cells during B cell differentiation in vivo","volume":"207","author":"Patterson","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.117240_bib35","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/bloodadvances.2023010218","article-title":"C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma","volume":"8","author":"Cheung","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2025.117240_bib36","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/bloodadvances.2020002711","article-title":"Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma","volume":"4","author":"Misiewicz-Krzeminska","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2025.117240_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111639","article-title":"Oleil Hydroxytyrosol (HTOL) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells","volume":"22","author":"Todoerti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117240_bib38","first-page":"2305","article-title":"Molecular basis and potential molecular mechanisms of action in natural products as therapeutic agents towards multiple myeloma, Trop","volume":"7","author":"Wijesekara","year":"2023","journal-title":"J. Nat. Prod. Res."},{"key":"10.1016\/j.ejmech.2025.117240_bib39","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117240_bib40","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3389\/fonc.2019.01261","article-title":"Hsa_circ_0007841: a novel potential biomarker and drug resistance for multiple myeloma","volume":"9","author":"Gao","year":"2019","journal-title":"Front. Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:30:08Z","timestamp":1740349808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["S0223523425000054"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117240","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117240"}}